iowaodes

Single cell transcriptomes reveal expression patterns of chemoreceptor genes in olfactory sensory neurons of the Caribbean

An embedded gene selection method using knockoffs optimizing neural network

 

Background: Gene choice refers to discover a small subset of discriminant genes from the gene expression profiles. The way to choose genes that have an effect on particular phenotypic traits successfully is a vital analysis work within the subject of biology. The neural community has higher becoming capability when coping with nonlinear information, and it will probably seize options robotically and flexibly. On this work, we suggest an embedded gene choice methodology utilizing neural community.

 

The essential genes may be obtained by calculating the burden coefficient after the coaching is accomplished. In an effort to remedy the issue of black field of neural community and additional make the coaching outcomes interpretable in neural community, we use the concept of knockoffs to assemble the knockoff characteristic genes of the unique characteristic genes. This methodology not solely make every characteristic gene to compete with one another, but additionally make every characteristic gene compete with its knockoff characteristic gene. This method may help to pick the important thing genes that have an effect on the decision-making of neural networks.

 

Outcomes: We use maize carotenoids, tocopherol methyltransferase, raffinose household oligosaccharides and human breast most cancers dataset to do verification and evaluation.

 

Conclusions: The experiment outcomes display that the knockoffs optimizing neural community methodology has higher detection impact than the opposite present algorithms, and specifically for processing the nonlinear gene expression and phenotype information.

 

iowaodes
iowaodes

Fenretinide

9417-10 each
EUR 222

Fenretinide

9417-50 each
EUR 705.6

 

Single cell transcriptomes reveal expression patterns of chemoreceptor genes in olfactory sensory neurons of the Caribbean spiny lobster, Panulirus argus

 

 

Background: Crustaceans categorical a number of courses of receptor genes of their antennules, which home olfactory sensory neurons (OSNs) and non-olfactory chemosensory neurons. Transcriptomics research reveal that candidate chemoreceptor proteins embrace variant Ionotropic Receptors (IRs) together with each co-receptor IRs and tuning IRs, Transient Receptor Potential (TRP) channels, Gustatory Receptors, epithelial sodium channels, and sophistication A G-protein coupled receptors (GPCRs). The Caribbean spiny lobster, Panulirus argus, expresses in its antennules almost 600 IRs, 17 TRP channels, 1 Gustatory Receptor, 7 epithelial sodium channels, 81 GPCRs, 6 G proteins, and dozens of enzymes in signaling pathways.

 

Nevertheless, the precise combinatorial expression patterns of those proteins in single sensory neurons usually are not recognized for any crustacean, limiting our understanding of how their chemosensory techniques encode chemical high quality.

 

Outcomes: The purpose of this research was to make use of transcriptomics to explain expression patterns of chemoreceptor genes in OSNs of P. argus. We generated and analyzed transcriptomes from 7 single OSNs, a few of which have been proven to answer a meals odor, in addition to a further 7 multicell transcriptomes from preparations containing few (2-4), a number of (ca. 15), or many (ca. 400) OSNs. We discovered that every OSN expressed the identical 2 co-receptor IRs (IR25a, IR93a) however

 

not the opposite 2 antennular coIRs (IR8a, IR76b), 9-53 tuning IRs however just one to some in excessive abundance, the identical 5 TRP channels plus as much as 5 extra TRPs, 12-17 GPCRs together with the identical 5 expressed in each single cell transcriptome, the identical Three G proteins plus others, many enzymes within the signaling pathways, however no Gustatory Receptors or epithelial sodium channels. The best distinction in receptor expression among the many OSNs was the identification of the tuning IRs.

 

Conclusions: Our outcomes present an preliminary view of the combinatorial expression patterns of receptor molecules in single OSNs in a single species of decapod crustacean, together with receptors straight concerned in olfactory transduction and others doubtless concerned in modulation. Our outcomes additionally counsel variations in receptor expression in OSNs vs. different chemosensory neurons.

Camel Genetic Assets Conservation by Tourism: A Key Sociocultural Method of Camelback Leisure Driving

 

  • Camels are unique parts, which may be comprised inside journey journey corporations selling ecotourism actions. Such recreations contribute to sustainable livelihoods for native communities and academic empowerment in the direction of nature and its conservation. At current, some native camel breeds’ survival reduces to this animal-based leisure business and its reliability to carry out and promote custom-made companies By conducting an on-site questionnaire to prospects taking part in camelback driving excursions, we assessed the motivational components affecting participation, satisfaction, and loyalty on this tourism phase that will have made it socially differentiated.

 

  • The sixfold mixture of workers efficiency, tradition geography, numerous and humane shut interplay, camel conduct and efficiency, sociotemporal context, and constructive earlier expertise includes the fundamental dimensions that designate buyer satisfaction and return intention chance inside this leisure enterprise.

 

  • Buyer data is crucial for stakeholders to construct personalised driving experiences and align income with environmental sustainability and biodiversity mainstream considerations into their on a regular basis operations. In flip, home camel vacationer rides might be managed as a viable path to nature conservation by serving to endangered native breeds to keep away from their useful devaluation and potential extinction.

 

gel casting base for evs3100

EVS3100-BASE ea
EUR 361.2

gel casting base for evs3200

EVS3200-BASE ea
EUR 361.2

gel casting base for evs3300

EVS3300-BASE ea
EUR 361.2

Rucaparib (free base)

A8893-10 10 mg
EUR 240
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway.

Rucaparib (free base)

A8893-200 200 mg
EUR 1243.2
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway.

Rucaparib (free base)

A8893-5 5 mg
EUR 164.4
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway.

Rucaparib (free base)

A8893-5.1 10 mM (in 1mL DMSO)
EUR 170.4
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway.

Rucaparib (free base)

A8893-50 50 mg
EUR 547.2
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway.

R406 (free base)

A5880-100 100 mg
EUR 1452
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins.

R406 (free base)

A5880-25 25 mg
EUR 616.8
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins.

R406 (free base)

A5880-5 5 mg
EUR 199.2
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins.

R406 (free base)

A5880-5.1 10 mM (in 1mL DMSO)
EUR 316.8
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins.

R406 (free base)

A5880-S Evaluation Sample
EUR 97.2
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins.

AZD4547, Free Base

ADC-P-063 unit Ask for price

AZD8055, Free Base

ADC-P-064 unit Ask for price

Cyclopamine, Free Base

ADC-P-079 unit Ask for price

Ixabepilone, Free Base

ADC-P-104 unit Ask for price

R406(free base)

E1KS1533 2mg
EUR 625.2

Ruxolitinib (free base)

10-042 25 mg
EUR 418.2
Description: Antineoplastic, anti-inflammatory and immunomodulating agent. Orally bioavailable potent ATP mimetic that inhibits both JAK1 and JAK2 with IC50 values of 2.7 and 4.5nM, respectively and is less selective for JAK3 (IC50=322nM). Affects DC differentiation and function, leading to impaired T cell activation. Used in the treatment of myeloproliferative neoplasms and psoriasis. Anticancer agent. Shown to induce apoptosis and autophagy. Potent and selective inhibitor of HIV-1 replication and virus reactivation in vitro. It is investigated against the spread of the SARS-CoV-2 (COVID-19).

LY2835219 free base

A3575-100 100 mg
EUR 686.4
Description: LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity.

LY2835219 free base

A3575-25 25 mg
EUR 309.6
Description: LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity.

LY2835219 free base

A3575-5 5 mg
EUR 170.4
Description: LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity.

PLX5622 (free base)

B2965-25 25 mg
EUR 903.6

PLX5622 (free base)

B2965-5 5 mg
EUR 272.4

YM158 (free base)

HY-U00355 1mg
EUR 2770.8

Vatalanib (free base)

HY-10203 5mg
EUR 142.8

Masupirdine (free base)

HY-109118 1mg
EUR 267.6

R406 (free base)

HY-11108 10mM/1mL
EUR 277.2

ITI214 (free base)

HY-12501 100mg
EUR 3531.6

AS2863619 (free base)

HY-126675 5mg
EUR 1410

AZD3839 (free base)

HY-13438 50mg
EUR 1216.8

Ripasudil free base

HY-15685A 10mg
EUR 489.6

RPR107393 free base

HY-100299 1mg
EUR 577.2

FR167344 free base

HY-100301 1mg
EUR 3164.4

FR183998 free base

HY-100302 1mg
EUR 1352.4

FR194738 free base

HY-100303 1mg
EUR 2388

Xylazine (free base)

Q-1445.0025 25.0g
EUR 385.2
Description: Sum Formula: C12H16N2S; CAS# [7361-61-7]

TMB free base

TB0954 1g
EUR 85.06

Apatinib (Free base)

B1613-25 each
EUR 496.8

Apatinib (Free base)

B1613-5 each
EUR 170.4

Carubicin (Free base)

B1853-1 each
EUR 183.6

Carubicin (Free base)

B1853-5 each
EUR 548.4

Anlotinib, free base

B2156-25 each
EUR 705.6

Anlotinib, free base

B2156-5 each
EUR 222

FIPI (free base)

B2372-25 each
EUR 757.2

FIPI (free base)

B2372-5 each
EUR 235.2

Terbinafine (Free base)

B2423-250 each
EUR 248.4

Terbinafine (Free base)

B2423-50 each
EUR 144

THZ1 (Free base)

9664-25 each
EUR 1227.6

THZ1 (Free base)

9664-5 each
EUR 352.8

MCC950 (Free base)

B1031-1 each
EUR 183.6

MCC950 (Free base)

B1031-5 each
EUR 548.4

Vatalanib, Free Base

2026-25 each
EUR 366

Vatalanib, Free Base

2026-5 each
EUR 151.2

Erlotinib, Free Base

2048-100 each
EUR 189.6

Erlotinib, Free Base

2048-1000 each
EUR 464.4

Sunitinib, Free base

2097-100 each
EUR 229.2

Sunitinib, Free base

2097-1000 each
EUR 601.2

Sunitinib, Free base

2097-25 each
EUR 138

Lapatinib, Free base

2138-100 each
EUR 464.4

Lapatinib, Free base

2138-25 each
EUR 229.2

Ruxolitinib, Free base

2139-100 each Ask for price

Ruxolitinib, Free base

2139-25 each
EUR 639.6

Ruxolitinib, Free base

2139-5 each
EUR 248.4

Imatinib, Free base

2141-100 each
EUR 176.4

Imatinib, Free base

2141-1000 each
EUR 502.8

Linsitinib, Free base

2294-25 each
EUR 679.2

Linsitinib, Free base

2294-5 each
EUR 222

Tipifarnib, Free base

2296-1 each
EUR 170.4

Tipifarnib, Free base

2296-5 each
EUR 496.8

Cyclopamine, Free Base

27013 10 mg
EUR 130
Description: Cyclopamine inhibits activation of the Hedgehog response pathway by binding to and inhibiting the proto-oncogene Smoothened (SMO). The effects of oncogenic mutations that either activate SMO or inactivate the tumor suppressor Patched (Ptch) can be reversed by cyclopamine treatment. Cyclopamine has also been shown to induce apoptosis in colorectal adenoma cell lines, carcinoma-derived cell lines, and skin basal cell carcinomas and is being investigated as an anti-cancer drug.

Afatinib

A170-100MG 100mg
EUR 122.4

Afatinib

HY-10261 200mg
EUR 374.4

Afatinib

27009 25 mg
EUR 115
Description: Afatinib, also known as BIW-2992, is an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinases. Afatinib suppresses EGF-induced EGFR phosphorylation and cellular proliferation in various cell lines, including EGFR-overexpressing and HER2-expressing cell lines A431, NIH-3T3-HER2, NCI-N87 and BT-474.

SGI-1776 free base

A4192-10 10 mg
EUR 296.4
Description: SGI-1776 free base, N-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine, is a potent ATP-competitive inhibitor of the serine/threonine family of Pim kinase, an enzyme regulating cell survival.

SGI-1776 free base

A4192-5 5 mg
EUR 184.8
Description: SGI-1776 free base, N-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine, is a potent ATP-competitive inhibitor of the serine/threonine family of Pim kinase, an enzyme regulating cell survival.

SGI-1776 free base

A4192-5.1 10 mM (in 1mL DMSO)
EUR 199.2
Description: SGI-1776 free base, N-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine, is a potent ATP-competitive inhibitor of the serine/threonine family of Pim kinase, an enzyme regulating cell survival.

SGI-1776 free base

A4192-50 50 mg
EUR 630
Description: SGI-1776 free base, N-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine, is a potent ATP-competitive inhibitor of the serine/threonine family of Pim kinase, an enzyme regulating cell survival.

SGI-1776 free base

A4192-S Evaluation Sample
EUR 97.2
Description: SGI-1776 free base, N-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine, is a potent ATP-competitive inhibitor of the serine/threonine family of Pim kinase, an enzyme regulating cell survival.

AM-095 free base

A3167-10 10 mg
EUR 254.4
Description: AM095 is a novel, potent and orally bioavailable antagonist of lysophosphatidic acid type 1 receptor (LPA1) with IC50 values of 0.73 and 0.98 ?M for mouse or recombinant human LPA1, respectively [1].

AM-095 free base

A3167-100 100 mg
EUR 964.8
Description: AM095 is a novel, potent and orally bioavailable antagonist of lysophosphatidic acid type 1 receptor (LPA1) with IC50 values of 0.73 and 0.98 ?M for mouse or recombinant human LPA1, respectively [1].

AM-095 free base

A3167-200 200 mg
EUR 1382.4
Description: AM095 is a novel, potent and orally bioavailable antagonist of lysophosphatidic acid type 1 receptor (LPA1) with IC50 values of 0.73 and 0.98 ?M for mouse or recombinant human LPA1, respectively [1].

AM-095 free base

A3167-5 5 mg
EUR 199.2
Description: AM095 is a novel, potent and orally bioavailable antagonist of lysophosphatidic acid type 1 receptor (LPA1) with IC50 values of 0.73 and 0.98 ?M for mouse or recombinant human LPA1, respectively [1].

AM-095 free base

A3167-50 50 mg
EUR 686.4
Description: AM095 is a novel, potent and orally bioavailable antagonist of lysophosphatidic acid type 1 receptor (LPA1) with IC50 values of 0.73 and 0.98 ?M for mouse or recombinant human LPA1, respectively [1].

L-Arginine free base

AB0205 100g
EUR 75.78

Staurosporine, >99% Free Base

BC090-001 1mg
EUR 295.2

Staurosporine, >99% Free Base

BC090-005 5mg
EUR 408

Vandetanib, >99% Free Base

BC098-025 25mg
EUR 278.4

Vandetanib, >99% Free Base

BC098-050 50mg
EUR 343.2

Vandetanib, >99% Free Base

BC098-100 100mg
EUR 375.6

Vandetanib, >100% Free Base

BC098-500 500mg
EUR 789.6

SB-334867 free base

B3423-100 100 mg
EUR 718.8
Description: SB-334867 free base is a selective antagonist of orexin-1 receptor [1].Orexin-A and orexin-B are two peptides isolated from rat hypothalamus. They are involved in some physiological functions such as the control of feeding, energy metabolism and regulation of the sleep-wake cycle.

SB-334867 free base

B3423-25 25 mg
EUR 348
Description: SB-334867 free base is a selective antagonist of orexin-1 receptor [1].Orexin-A and orexin-B are two peptides isolated from rat hypothalamus. They are involved in some physiological functions such as the control of feeding, energy metabolism and regulation of the sleep-wake cycle.

SB-334867 free base

B3423-5 5 mg
EUR 153.6
Description: SB-334867 free base is a selective antagonist of orexin-1 receptor [1].Orexin-A and orexin-B are two peptides isolated from rat hypothalamus. They are involved in some physiological functions such as the control of feeding, energy metabolism and regulation of the sleep-wake cycle.

SB-334867 free base

B3423-5.1 10 mM (in 1mL DMSO)
EUR 157.2
Description: SB-334867 free base is a selective antagonist of orexin-1 receptor [1].Orexin-A and orexin-B are two peptides isolated from rat hypothalamus. They are involved in some physiological functions such as the control of feeding, energy metabolism and regulation of the sleep-wake cycle.

BMS-345541(free base)

B4655-10 10 mg
EUR 282
Description: BMS-345541(free base) is a selective inhibitor of IKK-1 and IKK-2 with IC50 value of 4?M and 0.3?M, respectively [1].IKK is also known as nuclear factor kappa-B kinase subunit inhibitor and involves in cytokine-activated intracellular signaling pathways.

BMS-345541(free base)

B4655-5 5 mg
EUR 205.2
Description: BMS-345541(free base) is a selective inhibitor of IKK-1 and IKK-2 with IC50 value of 4?M and 0.3?M, respectively [1].IKK is also known as nuclear factor kappa-B kinase subunit inhibitor and involves in cytokine-activated intracellular signaling pathways.

BMS-345541(free base)

B4655-50 50 mg
EUR 714
Description: BMS-345541(free base) is a selective inhibitor of IKK-1 and IKK-2 with IC50 value of 4?M and 0.3?M, respectively [1].IKK is also known as nuclear factor kappa-B kinase subunit inhibitor and involves in cytokine-activated intracellular signaling pathways.

GSK J4 free base

B5959-10 10 mg
EUR 447.6
Description: GSK J4 free base

GSK J4 free base

B5959-50 50 mg
EUR 1437.6
Description: GSK J4 free base

CP-319340(free base)

HY-U00270 5mg
EUR 1052.4

AV-412 (free base)

HY-10346A 5mg
EUR 207.6

SB-334867 (free base)

HY-10895A 10mg
EUR 258

SNT-207858 (free base)

HY-11030A 10mg
EUR 1093.2

APX-115 (free base)

HY-120801A 5mg
EUR 267.6

LY-2584702 (free base)

HY-12493 5mg
EUR 198

Genz-123346 (free base)

HY-12744 10mM/1mL
EUR 226.8

YHO-13351 (free base)

HY-12758A 10mM/1mL
EUR 211.2

JTV-519 (free base)

HY-15293A 5mg
EUR 680.4

RGB-286638 (free base)

HY-15504A 100mg
EUR 3364.8

DOV-216,303 (Free Base)

HY-18332C 10mM/1mL
EUR 590.4

FK-448 Free base

HY-100193 10mg
EUR 2264.4

KW-8232 free base

HY-100304 10mg
EUR 6021.6

YM-53601 free base

HY-100313 1mg
EUR 1870.8

Z-NHNH2 (free base)

Q-1150.0025 25.0g
EUR 151.2
Description: Sum Formula: C8H10N2O2; CAS# [5331-43-1]

Z-NHNH2 (free base)

Q-1150.0100 100.0g
EUR 385.2
Description: Sum Formula: C8H10N2O2; CAS# [5331-43-1]

BMS-345541 (Free base)

B1907-1 each
EUR 170.4

BMS-345541 (Free base)

B1907-5 each
EUR 496.8

UNC-926, free base

B2158-25 each
EUR 757.2

UNC-926, free base

B2158-5 each
EUR 235.2

StemRegenin 1, Free base

2642-1 each
EUR 157.2

StemRegenin 1, Free base

2642-5 each
EUR 398.4

GSK-J4 (Free base)

2762-1 each
EUR 144

GSK-J4 (Free base)

2762-5 each
EUR 314.4

RGB-286638,  free base

2886-25 each
EUR 907.2

RGB-286638,  free base

2886-5 each
EUR 274.8

SGI-1776 free base

27651-1 5 mg
EUR 155
Description: SGI-1776 is a potent ATP-competitive inhibitor of the serine/threonine family of Pim kinase, an enzyme regulating cell survival. Through extensive biomedical characterization, SGI-1776 exhibits specificity to the three isoforms of the Pim family, including Pim-1, Pim-2, and Pim-3. Treatment with SGI-1776 induces apoptosis in CLL primary cell line.

SGI-1776 free base

27651-2 10 mg
EUR 235
Description: SGI-1776 is a potent ATP-competitive inhibitor of the serine/threonine family of Pim kinase, an enzyme regulating cell survival. Through extensive biomedical characterization, SGI-1776 exhibits specificity to the three isoforms of the Pim family, including Pim-1, Pim-2, and Pim-3. Treatment with SGI-1776 induces apoptosis in CLL primary cell line.

SGI-1776 free base

27651-3 50 mg
EUR 510
Description: SGI-1776 is a potent ATP-competitive inhibitor of the serine/threonine family of Pim kinase, an enzyme regulating cell survival. Through extensive biomedical characterization, SGI-1776 exhibits specificity to the three isoforms of the Pim family, including Pim-1, Pim-2, and Pim-3. Treatment with SGI-1776 induces apoptosis in CLL primary cell line.

Afatinib dimaleate

A3145-10 10 mg
EUR 265.2
Description: Afatinib is an irreversible EGFR/HER2 inhibitor with an IC50 of 14 nM for in vitro potency against HER2.

Afatinib dimaleate

A3145-5 5 mg
EUR 176.4
Description: Afatinib is an irreversible EGFR/HER2 inhibitor with an IC50 of 14 nM for in vitro potency against HER2.

Afatinib dimaleate

A3145-5.1 10 mM (in 1mL DMSO)
EUR 142.8
Description: Afatinib is an irreversible EGFR/HER2 inhibitor with an IC50 of 14 nM for in vitro potency against HER2.

Afatinib dimaleate

A3145-50 50 mg
EUR 614.4
Description: Afatinib is an irreversible EGFR/HER2 inhibitor with an IC50 of 14 nM for in vitro potency against HER2.

Afatinib (BIBW2992)

A8247-10 10 mg
EUR 265.2
Description: Afatinib (BIBW2992), an irreversible inhibitor of the ErbB family of tyrosine kinases, downregulates ErbB signalling by binding to the kinase domains of epidermal growth factor receptor (EGFR)/ human epidermal growth factor receptor 2 (HER2) with IC50 of 0.5 nM and 14nM, respectively.

Afatinib (BIBW2992)

A8247-5 5 mg
EUR 176.4
Description: Afatinib (BIBW2992), an irreversible inhibitor of the ErbB family of tyrosine kinases, downregulates ErbB signalling by binding to the kinase domains of epidermal growth factor receptor (EGFR)/ human epidermal growth factor receptor 2 (HER2) with IC50 of 0.5 nM and 14nM, respectively.

Afatinib (BIBW2992)

A8247-5.1 10 mM (in 1mL DMSO)
EUR 292.8
Description: Afatinib (BIBW2992), an irreversible inhibitor of the ErbB family of tyrosine kinases, downregulates ErbB signalling by binding to the kinase domains of epidermal growth factor receptor (EGFR)/ human epidermal growth factor receptor 2 (HER2) with IC50 of 0.5 nM and 14nM, respectively.

Afatinib (BIBW2992)

A8247-50 50 mg
EUR 614.4
Description: Afatinib (BIBW2992), an irreversible inhibitor of the ErbB family of tyrosine kinases, downregulates ErbB signalling by binding to the kinase domains of epidermal growth factor receptor (EGFR)/ human epidermal growth factor receptor 2 (HER2) with IC50 of 0.5 nM and 14nM, respectively.

Afatinib (BIBW2992)

A8247-S Evaluation Sample
EUR 97.2
Description: Afatinib (BIBW2992), an irreversible inhibitor of the ErbB family of tyrosine kinases, downregulates ErbB signalling by binding to the kinase domains of epidermal growth factor receptor (EGFR)/ human epidermal growth factor receptor 2 (HER2) with IC50 of 0.5 nM and 14nM, respectively.

Afatinib (dimaleate)

HY-10261A 200mg
EUR 374.4

Human Free PSA (f-PSA) ELISA Kit

PRB-5049-FREE 96 assays
EUR 686.4

H-Tyr-OEt (free base)

E-2900.0025 25.0g
EUR 166.8
Description: Sum Formula: C11H15NO3; CAS# [949-67-7]

H-Tyr-OEt (free base)

E-2900.0100 100.0g
EUR 428.4
Description: Sum Formula: C11H15NO3; CAS# [949-67-7]

Biotin ethylenediamine (free base form)

90071 25MG
EUR 158.4
Description: Minimum order quantity: 1 unit of 25MG

biotin cadaverine, free base form

90079 50MG
EUR 258
Description: Minimum order quantity: 1 unit of 50MG

SB 202190, >99% Free Base

BC086-025 25mg
EUR 246

SB 202190, >99% Free Base

BC086-050 50mg
EUR 295.2

SB 203580, >99% Free Base

BC087-025 25mg
EUR 262.8

SB 203580, >99% Free Base

BC087-050 50mg
EUR 343.2

Glyoxalase I inhibitor (free base)

HY-15167A 50mg
EUR 3036

Bay 65-1942 (free base)

HY-50949 10mg
EUR 1282.8

Gastrofensin AN 5 free base

HY-100296 5mg
EUR 2544

EZSolution? StemRegenin 1, Free base

2643-1 each
EUR 170.4

BAY 43-9006, Free base

2142-100 each
EUR 502.8

BAY 43-9006, Free base

2142-25 each
EUR 202.8

BAY 58-2667 (Free base)

2452-1 each
EUR 424.8

BAY 58-2667 (Free base)

2452-5 each
EUR 1358.4

H-Arg(Mtr)-OtBu (free base)

E-3075.0001 1.0g
EUR 370.8
Description: Sum Formula: C20H34N4O5S; CAS# [115608-61-2]

H-Arg(Mtr)-OtBu (free base)

E-3075.0005 5.0g
EUR 1371.6
Description: Sum Formula: C20H34N4O5S; CAS# [115608-61-2]

H-Arg(Pmc)-OtBu (free base)

E-3085.0001 1.0g
EUR 501.6
Description: Sum Formula: C24H40N4O5S; CAS# [169543-81-1]

H-Arg(Pmc)-OtBu (free base)

E-3085.0005 5.0g
EUR 1864.8
Description: Sum Formula: C24H40N4O5S; CAS# [169543-81-1]

biotin-x cadaverine, free base form

90080 20MG
EUR 258
Description: Minimum order quantity: 1 unit of 20MG

Cyclosporin A-Derivative 1 (Free base)

HY-P1355A 1mg
EUR 267.6

PNU-282987 (S enantiomer free base)

HY-12560D 5mg
EUR 1216.8

Human Free PSA (f-PSA) ELISA Kit

PRB-5049-FREE-5 5 x 96 assays
EUR 2739.6

CHIR 99021, GSK-3 Inhibitor , Free Base

BC212-002 2 mg
EUR 213.6

CHIR 99021, GSK-3 Inhibitor , Free Base

BC212-005 5 mg
EUR 318

CHIR 99021, GSK-3 Inhibitor , Free Base

BC212-010 10 mg
EUR 378

CHIR 99021, GSK-3 Inhibitor , Free Base

BC212-025 25 mg
EUR 472.8

CHIR 99021, GSK-3 Inhibitor , Free Base

BC212-100 100 mg
EUR 1064.4

H-Ala-Ala-Phe-AMC (free base)

I-1415.0050 50.0mg
EUR 181.2
Description: Sum Formula: C25H28N4O5; CAS# [62037-41-6]

H-Ala-Ala-Phe-AMC (free base)

I-1415.0250 250.0mg
EUR 618
Description: Sum Formula: C25H28N4O5; CAS# [62037-41-6]

(D-Ser(tBu)6,Azagly10)-LHRH (free base)

H-7296.0005 5.0mg
EUR 219.6
Description: Sum Formula: C59H84N18O14; CAS# [65807-02-5]

(D-Ser(tBu)6,Azagly10)-LHRH (free base)

H-7296.0025 25.0mg
EUR 769.2
Description: Sum Formula: C59H84N18O14; CAS# [65807-02-5]

casting base

EHS3100-CAST ea
EUR 128.4

casting base

EHS3200-CAST ea
EUR 148.8

casting base

EHS3300-CAST ea
EUR 148.8

Tris-base

20-abx082498
  • EUR 393.60
  • EUR 243.60
  • EUR 493.20
  • 1 kg
  • 500 g
  • 5 kg

Tetracycline base

GA9779-100G 100 g
EUR 180

Tetracycline base

GA9779-10G 10 g
EUR 55.2

Tetracycline base

GA9779-25G 25 g
EUR 74.4

Rimonabant base

GX9120-10MG 10 mg
EUR 103.2

Rimonabant base

GX9120-25MG 25 mg
EUR 156

ProteoIQ Base

PS2 1
EUR 5114.4

Vincamine base

Q-1435.0005 5.0g
EUR 270
Description: Sum Formula: C21H26N2O3; CAS# [1617-90-9]

Vincamine base

Q-1435.0025 25.0g
EUR 963.6
Description: Sum Formula: C21H26N2O3; CAS# [1617-90-9]

Positioning Base

S44I041002 EACH
EUR 1409.04

Leave a Reply

Your email address will not be published.